Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sundeep Ganoria headshot

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

by Sundeep Ganoria

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

Zacks Equity Research

Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View

by Zacks Equity Research

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

Zacks Equity Research

Initial Claims Increased Slightly More Than Expected

by Zacks Equity Research

Initial Claims Increased Slightly More Than Expected

Mark Vickery headshot

Ahead of Fed Decision, Big Earnings Wins for Forgotten Names

by Mark Vickery

The long-expected big news item for market participants this afternoon is the Fed interest rate move.

Zacks Equity Research

Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 101.59% and 47.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

by Kinjel Shah

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

Zacks Equity Research

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

by Sundeep Ganoria

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.

Zacks Equity Research

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?